Proteinuria

abate or applaud abatacept in proteinuric kidney disease?

Jochen Reiser, Nada Alachkar

Research output: Contribution to journalArticle

Abstract

T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.

Original languageEnglish (US)
Pages (from-to)128-130
Number of pages3
JournalNature Reviews Nephrology
Volume10
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Lupus Nephritis
Kidney Diseases
Proteinuria
CD80 Antigens
Focal Segmental Glomerulosclerosis
Podocytes
Lymphocyte Activation
B-Lymphocytes
T-Lymphocytes
Wounds and Injuries
Therapeutics
Abatacept
buprofezin

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Proteinuria : abate or applaud abatacept in proteinuric kidney disease? / Reiser, Jochen; Alachkar, Nada.

In: Nature Reviews Nephrology, Vol. 10, No. 3, 2014, p. 128-130.

Research output: Contribution to journalArticle

@article{e00fb33ddd364c389db0e6af30ee7ad0,
title = "Proteinuria: abate or applaud abatacept in proteinuric kidney disease?",
abstract = "T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.",
author = "Jochen Reiser and Nada Alachkar",
year = "2014",
doi = "10.1038/nrneph.2013.276",
language = "English (US)",
volume = "10",
pages = "128--130",
journal = "Nature Reviews Nephrology",
issn = "1759-507X",
publisher = "Nature Publishing Group",
number = "3",

}

TY - JOUR

T1 - Proteinuria

T2 - abate or applaud abatacept in proteinuric kidney disease?

AU - Reiser, Jochen

AU - Alachkar, Nada

PY - 2014

Y1 - 2014

N2 - T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.

AB - T-lymphocyte activation antigen CD80 is a B-cell costimulator and podocyte injury marker originally described in lupus nephritis; CD80 blockade with abatacept disappointed in a lupus nephritis trial. A study now suggests abatacept efficacy in focal and segmental glomerulosclerosis. Small patient numbers and concurrent treatment regimens call for more definitive studies regarding this therapeutic strategy.

UR - http://www.scopus.com/inward/record.url?scp=84906564596&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84906564596&partnerID=8YFLogxK

U2 - 10.1038/nrneph.2013.276

DO - 10.1038/nrneph.2013.276

M3 - Article

VL - 10

SP - 128

EP - 130

JO - Nature Reviews Nephrology

JF - Nature Reviews Nephrology

SN - 1759-507X

IS - 3

ER -